



Lumv^oaTM
veligrotug-vvze

For thyroid eye disease

Patient portrayal

Learn how Lumv^oa works fast to help relieve your symptoms

USE and IMPORTANT SAFETY INFORMATION

Use: Lumv^oa is a prescription medicine used to treat Thyroid Eye Disease (TED), no matter if you've had TED for months or years.

What is the most important information I should know about Lumv^oa?

Infusion reactions can happen during or soon after your infusion of Lumv^oa. Tell your doctor or nurse right away if you have any of these symptoms during or after your treatment with Lumv^oa:

- High blood pressure
- Chills
- Tiredness
- Feeling hot
- Headache

Please see additional Important Safety Information throughout.

Lumv^oaTM
veligrotug-vvze

About Lumvoa for thyroid eye disease

What is Lumvoa?

Lumvoa is a prescription medicine used to treat thyroid eye disease, also known as TED. Lumvoa can help relieve symptoms in people who are newly diagnosed or have been living with TED for a long time.



12-week treatment course with only **5 infusions**



Rapid relief with reduced eye bulging in **as early as 3 weeks**



Support to help you start and stay on treatment

IMPORTANT SAFETY INFORMATION (cont'd)

Lumvoa may worsen inflammatory bowel disease (IBD), such as Crohn's disease or ulcerative colitis. Tell your doctor right away if you have worsening IBD symptoms, which may include diarrhea with stomach pain or cramps, blood in your stools, sudden urgency to have a bowel movement, or feeling like you need to have a bowel movement even when there's little or no stool to pass.

2 Please see additional Important Safety Information throughout.

Lumvoa was studied in a range of people with TED

This included people recently diagnosed with TED as well as those who were living with TED for a long time.



301 people with TED

- 113 people recently diagnosed (active TED)
- 188 people with long-term (chronic TED)



Treatment over 12 weeks

People received a total of 5 infusions of Lumvoa over 12 weeks. Some people received a placebo (salt water) infusion on the same schedule for comparison.



What doctors looked at

- Primary measurement: effect on eye bulging at week 15
- Secondary measurement: effect on double vision at week 15



Lumvoa provides relief of TED symptoms

If you have been diagnosed within the last 15 months,
See the results below for active TED

Less eye bulging*

In active TED, improvement of eye bulging was seen as early as 3 weeks and continued to improve through week 15.

70% of people taking Lumvoa had reduced eye bulging at 15 weeks vs 5% with placebo (Lumvoa, n=75; Placebo, n=38).

71% of people who had reduced eye bulging at 15 weeks maintained their improvement at 52 weeks.

Improvement in double vision†

59% of people taking Lumvoa experienced improvement in double vision at 15 weeks vs 20% with placebo (Lumvoa n=50; Placebo n=26).

Double vision completely went away in **49% of people** taking Lumvoa vs 12% with placebo.

50% of people who experienced resolution at 15 weeks maintained their results at 52 weeks.

IMPORTANT SAFETY INFORMATION (cont'd)

Lumvoa may cause an increase in your blood sugar. Before starting treatment with Lumvoa, tell your doctor if you have high blood sugar or if you have diabetes. It is important for you to take your treatments and follow an appropriate diet for glucose control as prescribed by your doctor.

4 Please see additional Important Safety Information throughout.

Whether you've been recently diagnosed or have had TED for years, treatment with **Lumvoa may help reduce your symptoms**

If you were diagnosed more than 15 months ago,
See the results below for chronic TED

Less eye bulging*

In chronic TED, improvement of eye bulging was seen as early as 3 weeks and continued to improve through week 15.

57% of people taking Lumvoa had reduced eye bulging at 15 weeks vs 8% with placebo (Lumvoa n=125; Placebo n=63).

57% of people who had reduced eye bulging at 15 weeks maintained their improvement at 52 weeks.

Improvement in double vision†

In chronic TED, double vision went away in as early as 3 weeks in some people taking Lumvoa.

56% of people taking Lumvoa experienced improvement in double vision at 15 weeks vs 25% with placebo (Lumvoa n=65; Placebo n=37).

Double vision completely went away at 15 weeks in **32% of people** taking Lumvoa vs 14% with placebo.

80% of people who experienced resolution at 15 weeks maintained their improvement at 52 weeks.

*Change in eye bulging was measured at week 15. A patient was considered a responder if the treated eye moved back by at least 2 mm compared with the start of the study and the other eye did not worsen.

†Improvement in double vision was measured using a 4-point scale where scores ranged from 0 (no double vision) to 3 (constant double vision). Patients were considered responders if their double vision improved by 1 point from the start of the study by week 15. Complete resolution meant that patients who had double vision at the start of the study reported no double vision at week 15.

*Change in eye bulging was measured at week 15. A patient was considered a responder if the treated eye moved back by at least 2 mm compared with the start of the study and the other eye did not worsen.

†Improvement in double vision was measured using a 4-point scale where scores ranged from 0 (no double vision) to 3 (constant double vision). Patients were considered responders if their double vision improved by 1 point from the start of the study by week 15. Complete resolution meant that patients who had double vision at the start of the study reported no double vision at week 15.

Potential side effects of Lumvoa

The most common side effects (occurring in 5% or more of patients) were:

- Muscle spasms
- Headache
- Hearing problems
- High blood sugar
- Tiredness
- Diarrhea
- Ear discomfort
- Infusion reactions
- Nausea
- Cold-like symptoms
- Increased blood creatine phosphokinase (CPK)
- Dry skin
- High blood pressure

In clinical studies, most patients (94%) completed all 5 infusions of Lumvoa.

Most side effects were mild or moderate and got better during or after treatment.

Menstrual changes (such as irregular or missed periods) were reported in about 29% of menstruating women who took Lumvoa, compared with 6% of those who took placebo.

Lumvoa may cause hearing problems, including hearing loss. In some cases, hearing loss may be permanent. In clinical studies, most hearing-related events were mild, and most got better during or after treatment. Your doctor should check your hearing before, during, and after treatment.

Talk to your doctor if you are experiencing any side effects while on Lumvoa. These may not be all of the possible side effects of Lumvoa.



Getting started with Lumvoa

ViridianCares is here to help you start and stay on treatment

Once your doctor enrolls you in ViridianCares, you'll be paired with a Patient Access Liaison (PAL—your dedicated point of contact for personalized support every step of the way).

Your PAL can help you:



Navigate insurance coverage



Explore financial assistance options



Stay on track with your treatment schedule

You don't have to manage this journey alone. Your PAL is here to support you throughout your treatment journey.

Viridian understands that cost matters

Your PAL will review all financial support programs with you. Commercially insured patients may pay as little as \$0* for both medication and infusion costs through our Co-pay program.

*Patients must be enrolled in ViridianCares and meet all eligibility requirements. Patients with government insurance are not eligible for co-pay assistance.

See [terms & conditions](#).



Important Safety Information (cont'd)

Lumvoa may cause severe hearing problems including hearing loss, which in some cases may be permanent. Tell your doctor if you have any signs or symptoms of hearing problems or changes in hearing.

Before receiving Lumvoa, tell your doctor if you:

- Have inflammatory bowel disease (Crohn's disease or ulcerative colitis).
- Have diabetes or know your blood sugar is high.
- Are pregnant or plan to become pregnant. Lumvoa may harm your unborn baby. Tell your doctor if you become pregnant or suspect you are pregnant during treatment with Lumvoa. Women who are able to become pregnant should use an effective form of birth control (contraception) prior to starting treatment, during treatment, and for 6 months after the final dose of Lumvoa.
- Are breastfeeding or plan to breastfeed. It is not known if Lumvoa passes into your breast milk. Talk to your doctor about the best ways to feed your baby during treatment with Lumvoa.
- All the medicines you take, including prescription and over-the-counter medicines, vitamins, and dietary and herbal supplements. Know the medicines you take. Keep a list of them to show your doctor and pharmacist when you get a new medicine.

What are the possible side effects of Lumvoa?

The most common side effects of Lumvoa include muscle cramps or spasms, headache, hearing problems, high blood sugar, tiredness, diarrhea, ear discomfort, infusion reactions, nausea, cold-like symptoms, increases in a blood enzyme called creatine phosphokinase, dry skin, and high blood pressure.

This is not a complete list of all possible side effects. Tell your doctor or treatment team about any side effect you may have. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/safety/medwatch, or call 1-800-FDA-1088.

Lumvoa (500 mg) is an injection for infusion.

Please see Full Prescribing Information or visit Lumvoa.com for more information.

Notes about my treatment

[illegible]

VIRIDIANTM *cares*



For more information about
ViridianCares, call **1-866-VCARES1**,
Monday through Friday, 8 AM to 8 PM ET